Overview

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating non-smokers or former light smokers with relapsed or refractory stage IIIB or stage IV non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Ohio State University Comprehensive Cancer Center

Collaborator:

Bayer

Treatments:

Niacinamide
Sorafenib